Percutaneous microwave ablation and transcatheter arterial chemoembolization for serum tumor markers and prognostics of middle-late primary hepatic carcinoma

Table 3 Comparison of serum tumor marker levels between the two groups before treatment and 4 wk after treatment

Group	AFP (g/L)		CEA (g/mg)		CA19-9 (U/mL)
	Pre-treatment	After 4 wk of treatment	Pre-treatment	After 4 wk of treatment	Pre-treatment	After 4 wk of treatment
Combined group (n = 75)	364.17 ± 50.46	212.52 ± 39.522	19.44 ± 2.05	11.02 ± 2.182	239.87 ± 40.16	170.25 ± 28.281
Single group (n = 75)	361.74 ± 51.78	256.23 ± 42.11	19.32 ± 2.11	13.56 ± 2.40	240.56 ± 40.22	189.54 ± 38.84
t value	-0.290	-6.553	0.325	-6.770	-0.105	-3.477
P value	0.772	< 0.001	0.746	< 0.001	0.916	0.001

¹P < 0.01 vs single group.

²P < 0.001 vs single group.

AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9.